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Abstract: Twenty years ago, Kaposi’s sarcoma (KS) was the oncologic counterpart to 
Winston Churchill’s Russia: a riddle, wrapped in a mystery, inside an enigma. First 
described by Moritz Kaposi in 1872, who reported it to be an aggressive skin tumor, KS 
became known over the next century as a slow-growing tumor of elderly men—in fact, 
most KS patients were expected to die with the tumor rather than from it. Nevertheless, the 
course and manifestations of the disease varied widely in different clinical contexts. The 
puzzle of KS came to the forefront as a harbinger of the AIDS epidemic. The articles in 
this issue of Viruses recount progress made in understanding Kaposi’s sarcoma herpesvirus 
(KSHV) since its initial description in 1994. 
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Kaposi’s early microscopic studies revealed KS to be a complex tumor composed of disorganized 
endothelial cell proliferations forming blood-filled vascular clefts but also containing areas of 
organized micro-neovascularization and often with an inflammatory infiltrate. Pathologists and 
clinicians became suspicious of whether KS was a “true cancer”: most histopathologic examinations 
showed no clear demarcation of tumor margins, and the tumor often had a waxing and waning course. 
Although KS-like spindle cells could be grown in culture from KS lesions, these same cell 
proliferations could be also generated from blood, and were subsequently shown by Browning to be 
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circulating endothelial precursor cells [1]. Later it would be found that cultured “spindle cells” from 
KS tumor specimens do not retain the KSHV genome [2]. 
The epidemiology of KS was complex as well, but proved critical in deciphering the biology of 
KSHV. Early on, KS was thought to be most common among elderly Ashkenazi Jewish men and later 
was also reported in isolated European ethnic groups, particularly Sicilians and residents of the Po 
Valley [3]. By the 1950s, extraordinary rates of KS were recognized to occur in parts of Central and 
East Africa, where, in some cancer registries, KS was one of the most commonly-reported cancers [4]. 
Unlike European (or “classic”) KS, KS in Africa (“endemic KS”) could occur in children of both sexes 
where it had lymphadenopathic dissemination that was nearly always rapidly fatal [5]. Among African 
adults, KS still showed predisposition to males over females but tended to also be more aggressive 
than the classic variant. With the development of transplantation treatment regimens and 
immunosuppression-promoting cancer therapies, a new and striking form of KS emerged in the  
1970s [6]. Iatrogenic KS differed dramatically from previous forms since it was highly aggressive, 
often fatal, and had a more balanced sex ratio. Studies of transplantation registries repeatedly reveal 
that KS is the most significantly elevated cancer among transplant patients [7]. These odd geographic 
and epidemiologic patterns suggested to some that KS might be a cancer caused by a virus.  
Emergence of the AIDS epidemic in the early 1980s focused scientific attention on this curious 
cancer [8]. Previously healthy young men were suddenly being struck by disseminated KS as well as 
other, previously-rare infections mainly seen among highly immune suppressed transplant patients. 
The aggressiveness of this AIDS-related cancer left little doubt that it was under immune control. 
Discovery of the human immunodeficiency virus in 1983–1984 made clear that AIDS is caused by a 
retroviral ablation of CD4+ T cells, but how and why do AIDS patients get this cancer? 
Epidemiologists described yet again new patterns for “epidemic” or AIDS-KS: the disease occurred 
almost exclusively among the subset of gay and bisexual men with AIDS (These patterns refer 
exclusively to North American and European populations. In Africa, there was an explosive epidemic 
of KS together with the HIV epidemic that affected virtually all populations: children and adults; 
homosexuals and heterosexuals; and men and women [9]). 
By this time, the concept that tumor cells emerge after multiple genetic hits was widely held, and 
the patterns of KS occurrence remained mysterious. First, KS preferentially occurred among  
men-who-have-sex-with-men and bisexual male AIDS patients—in fact, so commonly, that the 
established paradigm requiring multiple genetic hits to generate cancer could not apply. In contrast, KS 
was relatively rare among equally immune suppressed HIV+ but heterosexual men (such as persons 
with hemophilia or blood transfusion recipients). Despite the variety of clinical manifestations for KS, 
all the different forms of KS had indistinguishable pathologic features suggesting it is a single cancer 
having a common underlying cause. 
In a landmark epidemiologic study, Valerie Beral, Harold Jaffe and colleagues sorted out the 
evolving epidemiology of KS, taking into account not only AIDS-KS patterns but also a century’s 
worth of observations on KS occurrence prior to the AIDS epidemic [10]. Their conclusion was that 
AIDS-KS was caused by a sexually transmitted virus that had not yet been discovered since the agent 
did not fit the clinico-epidemiology patterns for any known virus at that time. The agent could be most 
efficiently transmitted through homosexual activity (although the precise sex behavior is still 
unknown) but it would not cause disease unless the infected person also developed severe immune 
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suppression. Further, while HIV is readily transmitted by blood-borne infection, the putative KS agent 
is not. Hence, transfusion recipients and persons with hemophilia could develop AIDS from HIV 
infection but would be at a low risk for AIDS-KS. Similar to some other viruses (e.g., hepatitis B 
virus), the agent might be transmitted through nonsexual mechanisms (that also still remain poorly 
understood) and developing country might have entirely different transmission patterns from those of 
developed countries. Geographically, the KS agent should be hyperendemic in sub-Saharan Africa, 
less so in nearby Mediterranean countries and lowest in North America, Northern Europe and Eastern 
Asia. Beral and Jaffe’s study inferred that the KS agent should be uncommon in the general  
U.S. population. 
By 1994, years of research had failed to reveal the identity of this agent. Over 20 different viruses, 
bacteria and environmental exposures had been proposed, but none of them fit the established patterns 
for KS. Many of these agents could be easily dismissed—the idea that recreational nitrite poppers act 
as mutagens for KS seemed potentially plausible for a subset of club-culture AIDS patients but 
certainly did not help explain KS among more sedentary gay men infected with HIV nor Africans or 
transplant patients. Other agents, such as cytomegalovirus (CMV), required years of replicative studies 
before the consensus conclusion was reached that CMV is not the cause for KS. HIV itself was 
promoted to cause KS by inducing inflammation. This inadequately explained KS occurring prior the 
AIDS epidemic or lack of KS among blood-recipients with AIDS and high HIV loads. The early 1990s 
was also a period of turmoil and frustration for scientists working on HIV/AIDS. Protest marches 
against AIDS and sit-in demonstrations at the U.S. Food and Drug Administration were commonplace. 
Enormous amounts had been learned about HIV, but death rates from AIDS continued to rise and the 
origins for KS remained obscure. 
Discovery of KSHV 
In early 1993, we had just moved to New York City, and the Department of Pathology at Columbia 
University generously provided a 100 square foot laboratory and $20,000 start-up funding to Chang to 
perform clinical neuropathology research. Moore had been an epidemiologist at the Centers for 
Disease Control working on meningitis epidemics and refugee disasters in Africa. He took a job in the 
New York City Department of Health. We had been married for five years but had never  
worked together. 
At this time, several events contributed to our interest in searching for a KS pathogen. Genome 
scanning techniques then held promise for identifying large chromosome regions mutated in tumors, 
and Chang became interested in using these techniques. Moore had been involved in the control of a 
1991 hemorrhagic fever epidemic in Nigeria. The cause turned out to be a variant yellow fever virus 
that was undetectable on standard diagnostic tests but could have been prevented with a cheap and 
effective vaccine had it been identified early in the outbreak. 
Molecular biology techniques developed for non-directed genomic searching—such as 
representational difference analysis (RDA) [11] described by the Lisitsyns and Wigler—seemed 
promising for identifying foreign DNA from agents in outbreak settings as well. RDA is a PCR-based 
method to kinetically-enrich for novel genomic differences between two complex tissue samples. At 
the time, most new viruses were identified by direct animal or cell culture inoculations and serologic 
tests but these traditional techniques had clearly been unsuccessful in finding a KS agent.  
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Lisitsyn et al. generously provided a detailed RDA protocol but our first pilot project to RDA isolate 
lambda phage DNA spiked into a human tissue sample failed. The costs for this experiment in buying 
Taq polymerase alone nearly broke our meagre start-up budget. We did not have other options than to 




Figure 1. Southern blotting with probes using cloned RDA products. Left panel probed 
with the KSBam330 band and right panel probed with the KSBam631 band. Lanes 1, 2, 3 
were DNA extracted from AIDS lymphomas; #2 is a PEL that strongly hybridized with 
both probes. A cell line established previously from this lymphoma was subsequently 
named BC-1. Lane #4 was DNA extracted from the KS lesion used for RDA tester and 
Lane #5 contained DNA the same patient’s healthy control skin that was for the RDA 
control driver. Lane #6 was PBMC DNA from another patient with KS lesions. 
In early May of 1993, Anna Batistatou, then a resident in the Department of Pathology at Columbia, 
alerted us to her autopsy on a middle-aged man with AIDS-KS. This case turned out to be unusual for 
several reasons: firstly, the concern of contracting HIV infection from a slipped scalpel during an 
AIDS autopsy had driven this procedure to a trickle by 1993. Batistatous’s AIDS autopsy case would 
be one of the last ones performed at Columbia for several years and, although we did not know it at the 
time, our major local source for KS tissues was soon to be gone. Secondly, we later found that this 
patient’s KS lesions had the highest KSHV load of any KS tumors that we subsequently collected. A 
KS lesion and a control skin sample were taken for RDA analysis, which was performed by Chang and 
Melissa Pessin, a rotating Pathology resident. The iterative protocol began on August 12 and four 
RDA bands were isolated on September 7 and cloned by September 15, 1993. 
Viruses 2014, 6 4262 
 
Given the possibility for PCR contamination, we chose to analyze the bands by the more time 
consuming, but dependable, Southern blotting technique. Detection would not be a problem since the 
KS agent should be present in every tumor cell. Further, a less sensitive technique would have the 
advantage of reducing false-positive results from a coincidental but non-causal infection. The films 
were developed on September 27, providing the first hint that something new might be present  
(Figure 1). The patient’s KS tumor was positive for two of the RDA fragments (the other two 
fragments appeared to be human DNA) and his control tissue was negative. We couldn’t ask for a 
more satisfying result in the patients samples—the DNA fragments were not a human polymorphic 
sequence artificially amplified by the RDA process and both probes were positive in the same pattern. 
Further, whatever agent was present in the sample was abundant and made of DNA.  
But there were mitigating concerns. We had earlier asked another Pathology resident, Anne 
Matsushima, for non-KS tissue samples from AIDS patients to use as negative controls. This would 
help ensure that we hadn’t isolated some opportunistic but unrelated pathogen DNA abundant in AIDS 
patients. She provided three AIDS lymphoma samples; one (Figure 1, Lane 2) had a signal that was an 
order of magnitude more intense than the AIDS KS tissue. The chance that Beral-Jaffe’s agent actually 
causes KS and is also present in 33% of randomly selected AIDS-lymphomas—at much higher copy 
number than KS—seemed extremely unlikely. 
With this paltry information and two unknown DNA sequences in hand, we began a collaboration 
with Ethel Cesarman and Dan Knowles. Out of 27 KS samples from the Hematopathology tissue bank, 
25 were positive for the RDA fragments on blinded testing together with other control non-KS tissues 
from AIDS and non-AIDS patients. After breaking the code, we double-checked the two negative 
samples and found one was comprised of degraded DNA and the other was not actually KS but had 
been mislabeled. Slowly, the pattern began to emerge that actually did fit the Beral-Jaffe agent. The 
possibility that we were misinterpreting due to some trivial but subtle mistake was a constant concern. 
So there was palpable relief when we learned from Robin Weiss and Thomas Schulz in the UK, who 
agreed to test their own KS samples, that the same results were independently reproducible [12]. As it 
turned out, the one positive AIDS lymphoma DNA we obtained from Anne Matsushima happened to 
be a rare specimen from a body cavity-based lymphoma (subsequently renamed to primary effusion 
lymphoma, PEL), now known to harbor 40–80 times more KSHV DNA than KS tumors. Of 193 AIDS 
lymphoma samples Cesarman later examined, only 8 were positive for KSHV DNA and all of these 
were PEL [13]. The only control tissues that were also occasionally positive were hyperplastic lymph 
nodes from AIDS patients. In August 1995, Soulier and colleagues would report that AIDS-related 
Castleman’s tissues—often presenting as lymph node hyperplasias—are also commonly infected  
by KSHV [14]. 
Another four more months passed before the RDA fragments could be shown to be from a new 
human herpesvirus, similar to but distinct from any known herpesvirus. The next 15 months were 
filled with nearly nonstop work screening lambda phage libraries, sequencing the virus, isolating it in 
PEL cell culture, developing serologic tests and testing more tumor specimens. All successful tumor 
viruses go through a peer-review version of the Kübler-Ross stages: first there is shock and denial, 
then anger, next bargaining and depression, and, finally, acceptance (Figure 2). The initial KSHV 
description was finally published in December 1994[15], which began another stage of exciting and 
sometimes stormy[16] research on this peculiar virus. Over the past 20 years, the combined efforts of 
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an extraordinary and talented group of scientists around the world has forced KS to begin to give up 
answers to some of its enigmatic and mysterious riddles. 
!
 
Figure 2. The first KSHV description was submitted to the journal Science on April 27, 
1994 and summarily rejected. More sequencing and conversations with the editor were 
required for the paper to be reconsidered. 
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